undamentalytics Newsletter
Sign in

Q32 Bio Inc. income statement

In fiscal 2025, Q32 Bio Inc. reported revenue of $53.7m, operating income of $16.9m (a 31.5% margin) and net income of $29.8m, or $2.42 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue4233431054
Research and development48891009398324819
General and administrative1722333738101818
Operating income−60−110−130−96−133−48−6617
Interest expense—————2——
Net interest income—————131
Income before tax———−961−87−4630
Income tax00001000
Net income−56−104−129−96−5−54−4830
Diluted EPS−$1.95−$2.47−$2.80−$1.73−$0.09−$153.96−$6.58$2.42
Diluted shares (average)29m42m46m55m57m—10m12m
EBITDA−59−104−122−88−132−48−6617

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Q32 Bio Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Q32 Bio Inc.